{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:26:07Z","timestamp":1792218367960,"version":"4.4.0"},"reference-count":252,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1016\/j.ejca.2010.10.013","type":"journal-article","created":{"date-parts":[[2010,11,21]],"date-time":"2010-11-21T04:13:04Z","timestamp":1290312784000},"page":"8-32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":909,"title":["2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours"],"prefix":"10.1016","volume":"47","author":[{"given":"M.S.","family":"Aapro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Bohlius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.A.","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lissandra Dal","family":"Lago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Peter","family":"Donnelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Kearney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.H.","family":"Lyman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Pettengell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.C.","family":"Tjan-Heijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Walewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien C.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Zielinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2010.10.013_b0005","doi-asserted-by":"crossref","first-page":"7974","DOI":"10.1200\/JCO.2004.00.7955","article-title":"Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study","volume":"23","author":"Timmer-Bonte","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0010","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1200\/JCO.2004.03.213","article-title":"Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin\u2019s lymphoma: a nationwide study","volume":"22","author":"Lyman","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0015","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1080\/1042819031000119262","article-title":"Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin\u2019s lymphoma receiving CHOP chemotherapy","volume":"44","author":"Lyman","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ejca.2010.10.013_b0020","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1002\/cncr.11827","article-title":"Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma","volume":"98","author":"Lyman","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2010.10.013_b0025","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1200\/JCO.2005.09.102","article-title":"First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study","volume":"23","author":"Vogel","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0030","first-page":"547","article-title":"Risk of neutropenic complications based on a prospective nationwide registry of cancer patients initiating systematic chemotherapy","volume":"23","author":"Wolff","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0035","first-page":"2425","volume":"3","author":"Wolff","year":"2005","journal-title":"J Support Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0040","doi-asserted-by":"crossref","first-page":"109","DOI":"10.6004\/jnccn.2008.0012","article-title":"Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice","volume":"6","author":"Crawford","year":"2008","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ejca.2010.10.013_b0045","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1086\/339215","article-title":"2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer","volume":"34","author":"Hughes","year":"2002","journal-title":"Clin Infect Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.ejca.2010.10.013_b0050","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1038\/sj.bjc.6605272","article-title":"Management of chemotherapy-associated febrile neutropenia","volume":"101","author":"Cameron","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2010.10.013_b0055","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/00002820-200505000-00001","article-title":"Quality of life and chemotherapy-induced neutropenia","volume":"28","author":"Padilla","year":"2005","journal-title":"Cancer Nurs"},{"key":"10.1016\/j.ejca.2010.10.013_b0060","first-page":"47","article-title":"Measuring health-related quality of life and neutropenia-specific concerns among older adults undergoing chemotherapy: validation of the Functional Assessment of Cancer Therapy-Neutropenia (FACT-N)","volume":"16","author":"Wagner","year":"2008","journal-title":"Support Care Cancer"},{"issue":"Suppl. 1","key":"10.1016\/j.ejca.2010.10.013_b0065","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1038\/sj.bjc.6605273","article-title":"Impact of effective prevention and management of febrile neutropenia","volume":"101","author":"Krell","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2010.10.013_b0070","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S0093-7754(03)00314-2","article-title":"Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia","volume":"30","author":"Crawford","year":"2003","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0075","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/annonc\/mdg019","article-title":"A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy","volume":"14","author":"Green","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0080","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/annonc\/mdf130","article-title":"Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer","volume":"13","author":"Holmes","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0085","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1200\/JCO.2002.20.3.727","article-title":"Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III\/IV breast cancer","volume":"20","author":"Holmes","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0090","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3109\/10428199709114168","article-title":"Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin\u2019s lymphoma: factors influencing chemotherapy administration. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"25","author":"Gisselbrecht","year":"1997","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ejca.2010.10.013_b0095","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/j.ejca.2006.05.002","article-title":"EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours","volume":"42","author":"Aapro","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2010.10.013_b0100","unstructured":"EMEA. Committee for medicinal products for human use summary of positive opinion for Hexal. <http:\/\/www.ema.europa.eu\/pdfs\/human\/opinion\/FilgrastimHexal_61910508en.pdf> [last accessed: 23rd April 2010]; 2008."},{"key":"10.1016\/j.ejca.2010.10.013_b0105","unstructured":"EMEA. Committee for medicinal products for human use summary of positive opinion for Zarzio. <http:\/\/www.ema.europa.eu\/pdfs\/human\/opinion\/Zarzio_57442608en.pdf> [last accessed: 23rd April 2010]; 2008."},{"key":"10.1016\/j.ejca.2010.10.013_b0110","unstructured":"EMEA. Committee for medicinal products for human use summary of positive opinion for tevagrastim. <http:\/\/www.ema.europa.eu\/humandocs\/Humans\/EPAR\/tevagrastim\/tevagrastim.htm> [last accessed: 23rd April 2010]; 2008."},{"key":"10.1016\/j.ejca.2010.10.013_b0115","unstructured":"EMEA. Committee for medicinal products for human use summary of positive opinion for filgrastim ratiopharm. <http:\/\/www.emea.europa.eu\/humandocs\/Humans\/EPAR\/filgrastimratiopharm\/filgrastimratiopharm.htm> [last accessed: 23rd April 2010]; 2008."},{"key":"10.1016\/j.ejca.2010.10.013_b0120","unstructured":"EMEA. Committee for medicinal products for human use summary of positive opinion for ratiograstim. <http:\/\/www.ema.europa.eu\/humandocs\/Humans\/EPAR\/ratiograstim\/ratiograstim.htm> [last accessed: 23rd April 2010]; 2008."},{"key":"10.1016\/j.ejca.2010.10.013_b0125","unstructured":"EMEA. Committee for medicinal products for human use summary of positive opinion for biograstim. <http:\/\/www.ema.europa.eu\/humandocs\/Humans\/EPAR\/biograstim\/biograstim.htm> [last accessed: 23rd April 2010]; 2008."},{"issue":"Suppl. 5","key":"10.1016\/j.ejca.2010.10.013_b0130","doi-asserted-by":"crossref","first-page":"v248","DOI":"10.1093\/annonc\/mdq195","article-title":"Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications","volume":"21","author":"Crawford","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0135","unstructured":"Chauhan R, Morgan S, Potter V. Guidelines for the management of febrile neutropenia in oncology patients. <http:\/\/www.nuh.nhs.uk\/nch\/antibiotics\/Full%20Guidelines\/Onc_neut_sepsisv5_200911_RATIFIED_pdf.pdf> [last accessed: 23rd April 2010]; 2009."},{"key":"10.1016\/j.ejca.2010.10.013_b0140","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/jnci\/90.16.1205","article-title":"Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B","volume":"90","author":"Budman","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2010.10.013_b0145","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1200\/JCO.1990.8.6.963","article-title":"Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis","volume":"8","author":"Kwak","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0150","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1056\/NEJM199504063321401","article-title":"Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up","volume":"332","author":"Bonadonna","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2010.10.013_b0155","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/oxfordjournals.annonc.a058619","article-title":"Prognostic significance of received relative dose intensity in non-Hodgkin\u2019s lymphoma patients: application to LNH-87 protocol. The GELA. (Groupe d\u2019Etude des Lymphomes de l\u2019Adulte)","volume":"4","author":"Lepage","year":"1993","journal-title":"Ann Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.ejca.2010.10.013_b0160","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/S0959-8049(99)00259-2","article-title":"Chemotherapy dose reduction and delay in clinical practice. Evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer","volume":"36","author":"Chang","year":"2000","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2010.10.013_b0165","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1002\/1097-0142(20010615)91:12<2246::AID-CNCR1255>3.0.CO;2-4","article-title":"Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma","volume":"91","author":"Mayers","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2010.10.013_b0170","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1056\/NEJM199405053301801","article-title":"Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma","volume":"330","author":"Wood","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2010.10.013_b0175","first-page":"19","article-title":"Impact of neutropenia on delivering planned chemotherapy for solid tumours","volume":"17","author":"Khan","year":"2008","journal-title":"Eur J Cancer Care (Engl)"},{"key":"10.1016\/j.ejca.2010.10.013_b0180","first-page":"121","article-title":"The importance of dose intensity in the outcome of chemotherapy","author":"Hryniuk","year":"1988","journal-title":"Important Adv Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0185","first-page":"1299","article-title":"Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study","volume":"16","author":"Pettengell","year":"2008","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ejca.2010.10.013_b0190","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00277-007-0399-y","article-title":"Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP","volume":"87","author":"Bosly","year":"2008","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ejca.2010.10.013_b0195","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10549-008-0018-1","article-title":"Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients","volume":"114","author":"Chirivella","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2010.10.013_b0200","first-page":"203","article-title":"Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer?","volume":"14","author":"Radosavljevic","year":"2009","journal-title":"J BUON"},{"key":"10.1016\/j.ejca.2010.10.013_b0205","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/cncr.24861","article-title":"Ten-year follow-up of a phase 2 study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor-prognosis, advanced-stage epithelial ovarian cancer","volume":"116","author":"Sarosy","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2010.10.013_b0210","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1200\/JCO.2000.18.20.3558","article-title":"2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel","volume":"18","author":"Ozer","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0215","unstructured":"National Comprehensive Cancer Network. Myeloid growth factors. <http:\/\/www.nccn.org\/> [last accessed: Feb 2009]."},{"key":"10.1016\/j.ejca.2010.10.013_b0220","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1634\/theoncologist.10-6-427","article-title":"Risk models for predicting chemotherapy-induced neutropenia","volume":"10","author":"Lyman","year":"2005","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2010.10.013_b0225","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/cncr.11882","article-title":"Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management","volume":"100","author":"Crawford","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2010.10.013_b0230","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3816\/SCT.2005.n.023","article-title":"Final results of a placebo-controlled study of filgrastim in small-cell lung cancer: exploration of risk factors for febrile neutropenia","volume":"3","author":"Crawford","year":"2005","journal-title":"Support Cancer Ther"},{"key":"10.1016\/j.ejca.2010.10.013_b0235","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejon.2008.10.003","article-title":"Docetaxel-related side effects and their management","volume":"13","author":"Baker","year":"2009","journal-title":"Eur J Oncol Nurs"},{"key":"10.1016\/j.ejca.2010.10.013_b0240","first-page":"225b","article-title":"Incidence of febrile neutropenia (FN) is directly related to duration of severe neutropenia (DSN) after myelosuppressive chemotherapy","volume":"21","author":"Meza","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0245","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1200\/JCO.2000.18.16.3038","article-title":"The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients","volume":"18","author":"Klastersky","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0250","first-page":"841","article-title":"Performance of a modified MASCC index score for identifying low-risk febrile neutropenic cancer patients","volume":"16","author":"de Souza Viana","year":"2008","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ejca.2010.10.013_b0255","doi-asserted-by":"crossref","unstructured":"Klastersky J, Awada A, Paesmans M, Aoun M. Febrile neutropenia: a critical review of the initial management. Crit Rev Oncol Hematol 2010 [Epub ahead of print].","DOI":"10.1016\/j.critrevonc.2010.03.008"},{"key":"10.1016\/j.ejca.2010.10.013_b0260","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1002\/cncr.21847","article-title":"Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients","volume":"106","author":"Kuderer","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2010.10.013_b0265","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1634\/theoncologist.12-8-1019","article-title":"Cancer-associated neutropenic fever: clinical outcome and economic costs of emergency department care","volume":"12","author":"Courtney","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2010.10.013_b0270","first-page":"303","article-title":"Factors influencing in-hospital length of stay and mortality in cancer patients suffering from febrile neutropenia","volume":"9","author":"Lal","year":"2008","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.ejca.2010.10.013_b0275","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1056\/NEJMoa050078","article-title":"Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas","volume":"353","author":"Cullen","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2010.10.013_b0280","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJMoa044097","article-title":"Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia","volume":"353","author":"Bucaneve","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2010.10.013_b0285","doi-asserted-by":"crossref","first-page":"979","DOI":"10.7326\/0003-4819-142-12_Part_1-200506210-00008","article-title":"Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients","volume":"142","author":"Gafter-Gvili","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejca.2010.10.013_b0290","doi-asserted-by":"crossref","unstructured":"Herbst C, Naumann F, Kruse EB, et al. Prophylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapy. Cochrane Database Syst Rev 2009:CD007107.","DOI":"10.1002\/14651858.CD007107.pub2"},{"key":"10.1016\/j.ejca.2010.10.013_b0295","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.ejca.2005.03.006","article-title":"Efficacy of oral prophylactic antibiotics in neutropenic afebrile oncology patients: a systematic review of randomised controlled trials","volume":"41","author":"van de Wetering","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2010.10.013_b0300","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/annonc\/mdm438","article-title":"Pegfilgrastim +\/\u2013 ciprofloxacin for primary prophylaxis with TAC (docetaxel\/doxorubicin\/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study","volume":"19","author":"von Minckwitz","year":"2008","journal-title":"Ann Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.ejca.2010.10.013_b0305","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1038\/sj.bjc.6605270","article-title":"Prevention of febrile neutropenia: use of prophylactic antibiotics","volume":"101","author":"Cullen","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2010.10.013_b0310","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.biopha.2005.06.008","article-title":"Fluoroquinolone resistance in hematopoietic stem cell transplant recipients with infectious complications","volume":"59","author":"Bonadio","year":"2005","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.ejca.2010.10.013_b0315","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1016\/j.ejca.2006.07.012","article-title":"Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma","volume":"42","author":"Younes","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2010.10.013_b0320","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1093\/annonc\/mdi264","article-title":"Chemotherapy dose intensity in non-Hodgkin\u2019s lymphoma: is dose intensity an emerging paradigm for better outcomes?","volume":"16","author":"Gregory","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0325","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1182\/blood-2003-06-2094","article-title":"Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL","volume":"104","author":"Pfreundschuh","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2010.10.013_b0330","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood-2003-06-2095","article-title":"Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL","volume":"104","author":"Pfreundschuh","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2010.10.013_b0335","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1200\/JCO.2000.18.2.395","volume":"18","author":"Thatcher","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0340","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1093\/annonc\/mdm539","article-title":"Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10\/00","volume":"19","author":"Fountzilas","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0345","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1038\/sj.bjc.6603085","article-title":"Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer","volume":"94","author":"Kummel","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2010.10.013_b0350","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1182\/blood-2006-07-035709","article-title":"Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: a phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON)","volume":"109","author":"Verdonck","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2010.10.013_b0355","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1093\/jnci\/djk028","article-title":"Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy","volume":"99","author":"Hershman","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2010.10.013_b0360","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/jnci\/djk057","article-title":"Granulocyte colony-stimulating factor: key (f)actor or innocent bystander in the development of secondary myeloid malignancy?","volume":"99","author":"Touw","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2010.10.013_b0365","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1200\/JCO.2009.25.8723","article-title":"Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review","volume":"28","author":"Lyman","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0370","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","article-title":"2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline","volume":"24","author":"Smith","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0375","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3747\/co.2008.198","article-title":"Canadian supportive care recommendations for the management of neutropenia in patients with cancer","volume":"15","author":"Kouroukis","year":"2008","journal-title":"Curr Oncol"},{"issue":"Suppl. 2","key":"10.1016\/j.ejca.2010.10.013_b0380","doi-asserted-by":"crossref","first-page":"ii89","DOI":"10.1093\/annonc\/mdm052","article-title":"Hematopoietic growth factors: ESMO recommendations for the application","volume":"18","author":"Greil","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0385","unstructured":"Gohil S, Sharma A, Harper-Wynne C. Comparison of rates of febrile neutropenia using FEC100\/Docetaxel100 chemotherapy in breast cancer patients with and without primary GCSF prophylaxis. In: National Cancer Research Institute Cancer Conference, 4\u20137 October, Birmingham, UK, 2009 [abstract B75]."},{"key":"10.1016\/j.ejca.2010.10.013_b0390","unstructured":"Scaife J, Matthews R, Jenkins P. Febrile neutropenia in patients receiving TAC chemotherapy for breast cancer. In: National Cancer Research Institute Cancer Conference, 5\u20138 October, Birmingham, UK; 2008 [abstract BOA14]."},{"key":"10.1016\/j.ejca.2010.10.013_b0395","unstructured":"Ali Z, O\u2019Reilly S, Zahoor T, Schofield P, Malik Z. Experience of febrile neutropenia and secondary G-CSF prophylaxis during FEC-D chemotherapy in Merseyside and Cheshire Cancer Network. In: National Cancer Research Institute Cancer Conference, 5\u20138 October, Birmingham, UK; 2008 [abstract B67]."},{"key":"10.1016\/j.ejca.2010.10.013_b0400","unstructured":"Head J, Archer C, Harper-Wynne C, et al. Rates of neutropaenic sepsis with the use of adjuvant FEC100-Docetaxel (FEC100\u2013T) chemotherapy in high-risk node-positive patients with early breast cancer; a UK perspective. In: National Cancer Research Institute Cancer Conference, 5\u20138 October, Birmingham, UK; 2008 [abstract B64]."},{"key":"10.1016\/j.ejca.2010.10.013_b0405","first-page":"187","article-title":"Fludarabine in the treatment of chronic lymphocytic leukemia: a review","volume":"5","author":"Ricci","year":"2009","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.ejca.2010.10.013_b0410","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1200\/JCO.2006.08.0762","article-title":"Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997","volume":"25","author":"Flinn","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0415","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/blood-2008-02-140582","article-title":"Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2010.10.013_b0420","doi-asserted-by":"crossref","unstructured":"Hallek M, Fingerle-Rowson G, Fink A-M, et al. First-line treatment with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a randomized phase III trial on behalf of an international group of investigators and the German CLL Study Group. Blood (ASH Annual Meeting Abstracts) 2009;114 [abstract 535].","DOI":"10.1182\/blood.V114.22.535.535"},{"key":"10.1016\/j.ejca.2010.10.013_b0425","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/annonc\/mdg118","article-title":"Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients","volume":"14","author":"Millward","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0430","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1200\/JCO.1995.13.11.2688","article-title":"Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study","volume":"13","author":"Gianni","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0435","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1200\/JCO.1998.16.2.716","volume":"16","author":"Fossa","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0440","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1023\/A:1012545507920","article-title":"Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study","volume":"12","author":"Tjan-Heijnen","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0445","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1200\/JCO.1998.16.9.2930","article-title":"Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial","volume":"16","author":"Ravaud","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0450","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1200\/JCO.1996.14.2.619","article-title":"Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia","volume":"14","author":"Vellenga","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0455","unstructured":"Brooks J, Chrischilles E, Chen-Hardee, SS. The implications of treatment effect heterogeneity on using cost-effectiveness analysis for optimal prescribing: the case of primary G-CSF for non-Hodgkin\u2019s lymphoma patients. in preparation."},{"key":"10.1016\/j.ejca.2010.10.013_b0460","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/annonc\/mdl401","article-title":"Feasibility, toxicity and quality of life of first-line chemotherapy with platinum\/paclitaxel in elderly patients aged > or=70 years with advanced ovarian cancer \u2013 a study by the AGO OVAR Germany","volume":"18","author":"Hilpert","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0465","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/j.1365-2141.2008.07514.x","article-title":"Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study","volume":"144","author":"Pettengell","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2010.10.013_b1265","first-page":"25","article-title":"Risk factors for neutropenic fever in lymphoma patients receiving chemotherapy","author":"Teegala","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0475","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/COC.0b013e318165c01d","article-title":"Identifying patients at high risk for neutropenic complications during chemotherapy for metastatic breast cancer with doxorubicin or pegylated liposomal doxorubicin: the development of a prediction model","volume":"31","author":"Dranitsaris","year":"2008","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0480","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1002\/cncr.22939","article-title":"Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy","volume":"110","author":"Shayne","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2010.10.013_b0485","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/annonc\/mdn655","article-title":"A general chemotherapy myelotoxicity score to predict febrile neutropenia in hematological malignancies","volume":"20","author":"Moreau","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0490","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/annonc\/mdn560","article-title":"Pretreatment haematological laboratory values predict for excessive myelosuppression in patients receiving adjuvant FEC chemotherapy for breast cancer","volume":"20","author":"Jenkins","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0495","doi-asserted-by":"crossref","unstructured":"Schwenkglenks M, Pettengell R, Jackisch C, et al. Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients: data from the INC-EU Prospective Observational European Neutropenia Study. Ann Oncol 2010 [Epub ahead of print].","DOI":"10.1007\/s00520-010-0840-y"},{"key":"10.1016\/j.ejca.2010.10.013_b0500","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3816\/SCT.2006.n.020","article-title":"The Severe Chronic Neutropenia International Registry: 10-Year follow-up report","volume":"3","author":"Dale","year":"2006","journal-title":"Support Cancer Ther"},{"key":"10.1016\/j.ejca.2010.10.013_b0505","first-page":"70","article-title":"Predicting the risk of neutropenic complications and reduced dose intensity in patients with early-stage breast cancer (ESBC): Results from a prospective nationwide registry","volume":"24","author":"Lyman","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0510","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1093\/annonc\/mdl321","article-title":"Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: a prospective study","volume":"18","author":"Alexandre","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0515","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/sj.bjc.6602412","article-title":"An analysis of the utilisation of chemoprophylaxis against Pneumocystis jirovecii pneumonia in patients with malignancy receiving corticosteroid therapy at a cancer hospital","volume":"92","author":"Worth","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2010.10.013_b0520","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1016\/S0959-8049(03)00662-2","article-title":"EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer","volume":"39","author":"Repetto","year":"2003","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2010.10.013_b0525","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0140-6736(09)60569-9","article-title":"Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial","volume":"373","author":"Pirker","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2010.10.013_b0530","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2010.10.013_b0535","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1200\/JCO.2007.14.5466","article-title":"Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil","volume":"27","author":"Reck","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0540","doi-asserted-by":"crossref","first-page":"15S","DOI":"10.1200\/jco.2008.26.15_suppl.lba1011","article-title":"Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO","volume":"26","author":"Miles","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0545","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1093\/annonc\/mdf222","article-title":"A randomized phase II study of sequential docetaxel and doxorubicin\/cyclophosphamide in patients with metastatic breast cancer","volume":"13","author":"Perez","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0550","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1200\/JCO.2005.05.078","article-title":"Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group","volume":"23","author":"von Minckwitz","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0555","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1200\/JCO.2004.08.125","article-title":"Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study","volume":"22","author":"Alba","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0560","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1200\/JCO.2003.04.040","article-title":"Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial","volume":"21","author":"Nabholtz","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0565","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1200\/JCO.2002.11.005","article-title":"Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial","volume":"20","author":"Biganzoli","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0570","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S1470-2045(07)70041-4","article-title":"Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial","volume":"8","author":"Martin","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0575","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.1995.13.7.1564","article-title":"Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer","volume":"13","author":"Chevallier","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0580","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1200\/JCO.2003.09.081","volume":"21","author":"Citron","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0585","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1200\/JCO.2003.05.135","volume":"21","author":"Therasse","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0590","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1200\/JCO.2000.18.12.2385","article-title":"Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic\/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8","volume":"18","author":"Norris","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0595","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1200\/JCO.2002.09.002","article-title":"Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results","volume":"20","author":"O\u2019Shaughnessy","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0600","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1200\/JCO.2001.19.3.612","volume":"19","author":"Fumoleau","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0605","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.critrevonc.2006.12.007","article-title":"Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer: a randomized phase 2 trial","volume":"64","author":"Romieu","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ejca.2010.10.013_b0610","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/sj.bjc.6604862","article-title":"A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer","volume":"100","author":"Jones","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2010.10.013_b0615","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/S0959-8049(97)10039-9","article-title":"Dose intensification of epidoxorubicin and cyclophosphamide in metastatic breast cancer: a randomised study with two schedules of granulocyte-macrophage colony stimulating factor","volume":"34","author":"Stoger","year":"1998","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2010.10.013_b0620","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1200\/JCO.1998.16.8.2651","volume":"16","author":"Levine","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0625","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1200\/JCO.1988.6.9.1377","article-title":"A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer","volume":"6","author":"Tannock","year":"1988","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0630","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/00000421-200108000-00001","article-title":"CMF (cyclophosphamide, methotrexate, 5\u2013fluorouracil) versus cnf (cyclophosphamide, mitoxantrone, 5\u2013fluorouracil) as adjuvant chemotherapy for stage II lymph-node positive breast cancer: a phase III randomized multicenter study","volume":"24","author":"Ron","year":"2001","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0635","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1200\/JCO.2001.19.6.1707","article-title":"Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial","volume":"19","author":"Jassem","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0640","doi-asserted-by":"crossref","first-page":"6908","DOI":"10.1200\/JCO.2005.03.099","article-title":"Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide","volume":"23","author":"Papaldo","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0645","first-page":"143","article-title":"European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer","volume":"9","author":"Ardizzoni","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2010.10.013_b0650","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0959-8049(93)90376-Q","article-title":"Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy","volume":"29A","author":"Trillet-Lenoir","year":"1993","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2010.10.013_b0655","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1200\/JCO.1999.17.2.658","article-title":"Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer","volume":"17","author":"von Pawel","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0660","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/jnci\/dji114","article-title":"Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer","volume":"97","author":"Lorigan","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2010.10.013_b0665","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1200\/JCO.1995.13.3.652","article-title":"Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer","volume":"13","author":"Woll","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0670","first-page":"305","article-title":"Dose-intensive weekly alternating chemotherapy for patients with small cell lung cancer: randomized trial, can it improve survival of patients with good prognostic factors?","volume":"7","author":"Masutani","year":"2000","journal-title":"Oncol Rep"},{"key":"10.1016\/j.ejca.2010.10.013_b0675","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/1097-0142(20010801)92:3<601::AID-CNCR1360>3.0.CO;2-K","article-title":"Randomized phase II study of cyclophosphamide, doxorubicin, and vincristine compared with single-agent carboplatin in patients with poor prognosis small cell lung carcinoma","volume":"92","author":"White","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2010.10.013_b0680","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1200\/JCO.2002.02.069","article-title":"Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923","volume":"20","author":"Ardizzoni","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0685","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.1200\/JCO.2008.21.3868","article-title":"Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222","volume":"27","author":"Le","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0690","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1200\/JCO.1998.16.6.2126","article-title":"Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group","volume":"16","author":"Furuse","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0695","first-page":"1045","article-title":"Moderate dose-intensive chemotherapy for patients with non-small cell lung cancer: randomized trial, can it improve survival of patients with good performance status?","volume":"6","author":"Masutani","year":"1999","journal-title":"Oncol Rep"},{"key":"10.1016\/j.ejca.2010.10.013_b0700","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.2004.06.070","article-title":"Phase II trial of cisplatin\/etoposide and concurrent radiotherapy followed by paclitaxel\/carboplatin consolidation for limited small-cell lung cancer: Southwest Oncology Group 9713","volume":"22","author":"Edelman","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0705","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/(SICI)1097-0142(19990215)85:4<855::AID-CNCR12>3.0.CO;2-R","article-title":"Increasing dose intensity of cisplatin-etoposide in advanced nonsmall cell lung carcinoma: a phase III randomized trial of the Spanish Lung Cancer Group","volume":"85","author":"Font","year":"1999","journal-title":"Cancer"},{"issue":"Suppl. 1","key":"10.1016\/j.ejca.2010.10.013_b0710","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1007\/s00280-002-0449-z","article-title":"Gemcitabine, ifosfamide and Navelbine (GIN): a platinum-free combination in advanced non-small-cell lung cancer (NSCLC)","volume":"49","author":"Baldini","year":"2002","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ejca.2010.10.013_b0715","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2010.10.013_b0720","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1200\/JCO.2003.12.046","article-title":"Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group","volume":"21","author":"Fossella","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0725","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1200\/JCO.1998.16.7.2459","article-title":"Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study","volume":"16","author":"Wozniak","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0730","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1200\/JCO.2001.19.13.3210","article-title":"Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial","volume":"19","author":"Kelly","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0735","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/annonc\/mdg109","article-title":"Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer","volume":"14","author":"Stathopoulos","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0740","first-page":"3","article-title":"Combination chemotherapy with paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in inoperable non-small cell lung cancer: a phase III randomized study. Preliminary results. Hellenic Cooperative Oncology Group","volume":"27","author":"Kosmidis","year":"2000","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0745","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1200\/JCO.2002.02.068","article-title":"Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer","volume":"20","author":"Scagliotti","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0750","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1200\/JCO.1999.17.1.12","article-title":"Randomized phase III study of gemcitabine\u2013cisplatin versus etoposide\u2013cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer","volume":"17","author":"Cardenal","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0755","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1200\/JCO.1994.12.6.1169","article-title":"ESHAP \u2013 an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study","volume":"12","author":"Velasquez","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0760","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/oxfordjournals.annonc.a058364","article-title":"E-SHAP: inadequate treatment for poor-prognosis recurrent lymphoma","volume":"4","author":"Johnson","year":"1993","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0765","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1159\/000066768","article-title":"Modified ESHAP as salvage chemotherapy for recurrent or refractory non-Hodgkin\u2019s lymphoma: results of a single-center study of 32 patients. Modified etoposide, methylprednisolone, cytarabine and cisplatin","volume":"48","author":"Ozturk","year":"2002","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ejca.2010.10.013_b0770","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.3324\/haematol.13440","article-title":"R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL\/TAMO study","volume":"93","author":"Martin","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.ejca.2010.10.013_b0775","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.1182\/blood-2002-10-3238","article-title":"CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial","volume":"101","author":"Osby","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2010.10.013_b0780","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1182\/blood.V80.6.1430.1430","article-title":"Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin\u2019s lymphoma: a randomized controlled trial","volume":"80","author":"Pettengell","year":"1992","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.ejca.2010.10.013_b0785","doi-asserted-by":"crossref","first-page":"i11","DOI":"10.1093\/annonc\/mdg703","article-title":"Outpatient-based ifosfamide, carboplatin and etoposide (ICE) chemotherapy in transplant-eligible patients with non-Hodgkin\u2019s lymphoma and Hodgkin\u2019s disease","volume":"14","author":"Hertzberg","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0790","doi-asserted-by":"crossref","unstructured":"158. Hertzberg MS, Crombie C, Benson W, Taper J, Gottlieb D, Bradstock KF. Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin\u2019s and Hodgkin\u2019s lymphoma. Ann Oncol 2006;17(Suppl. 4):iv25\u201330.","DOI":"10.1093\/annonc\/mdj995"},{"key":"10.1016\/j.ejca.2010.10.013_b0795","doi-asserted-by":"crossref","first-page":"9198","DOI":"10.1200\/JCO.2005.02.907","article-title":"ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin\u2019s lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi","volume":"23","author":"Gobbi","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0800","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(07)61125-8","article-title":"Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial","volume":"370","author":"Catovsky","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2010.10.013_b0805","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1080\/1042819031000067981","article-title":"ACOD, a modified CHOP regimen for elderly patients with aggressive non-Hodgkin\u2019s lymphoma","volume":"44","author":"Martinelli","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ejca.2010.10.013_b0810","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/10428190210177","article-title":"Primary treatment of low-grade non-Hodgkin\u2019s lymphoma with the combination of fludarabine and mitoxantrone: a phase II study of the Hellenic Cooperative Oncology Group","volume":"43","author":"Dimopoulos","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ejca.2010.10.013_b0815","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1200\/JCO.2007.13.1391","article-title":"Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers","volume":"26","author":"Wilson","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0820","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1365-2141.2006.06438.x","article-title":"Dose-adjusted EPOCH plus rituximab is an effective regimen in patients with poor-prognostic untreated diffuse large B-cell lymphoma: results from a prospective observational study","volume":"136","author":"Garcia-Suarez","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2010.10.013_b0825","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2010.10.013_b0830","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1038\/sj.bjc.6602514","article-title":"Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma","volume":"92","author":"Ng","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2010.10.013_b0835","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1600-0609.2007.00996.x","article-title":"GEMOX-R regimen is a highly effective salvage regimen in patients with refractory\/relapsing diffuse large-cell lymphoma: a phase II study","volume":"80","author":"Lopez","year":"2008","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.ejca.2010.10.013_b0840","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa022473","article-title":"Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin\u2019s disease","volume":"348","author":"Diehl","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2010.10.013_b0845","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1200\/JCO.2008.17.0910","article-title":"ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin\u2019s lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0850","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/annonc\/mdi023","article-title":"A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin\u2019s disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly)","volume":"16","author":"Ballova","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0855","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1177\/030089169408000609","article-title":"The role of granulocyte colony-stimulating factor (filgrastim) in maintaining dose intensity during conventional-dose chemotherapy with ABVD in Hodgkin\u2019s disease","volume":"80","author":"Silvestri","year":"1994","journal-title":"Tumori"},{"key":"10.1016\/j.ejca.2010.10.013_b0860","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3324\/haematol.10661","article-title":"Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin\u2019s lymphoma","volume":"92","author":"Santoro","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.ejca.2010.10.013_b0865","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1200\/JCO.2000.18.14.2733","article-title":"Docetaxel for patients with paclitaxel-resistant Mullerian carcinoma","volume":"18","author":"Verschraegen","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0870","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1200\/JCO.2003.10.082","article-title":"Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study","volume":"21","author":"Omura","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0875","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1200\/JCO.1996.14.12.3056","article-title":"Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study","volume":"14","author":"Creemers","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0880","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/sj.bjc.6601618","article-title":"A phase II study of sequential carboplatin, paclitaxel and topotecan in patients with previously untreated advanced ovarian cancer","volume":"90","author":"Guppy","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2010.10.013_b0885","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/djg036","article-title":"A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer","volume":"95","author":"du Bois","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2010.10.013_b0890","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ygyno.2004.05.021","article-title":"Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer","volume":"94","author":"Gordon","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0895","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ygyno.2003.09.021","article-title":"Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients. A Hellenic Cooperative Oncology Group Study","volume":"92","author":"Papadimitriou","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0900","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1200\/JCO.1998.16.1.255","article-title":"Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen","volume":"16","author":"Vaughn","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0905","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1200\/JCO.2001.19.10.2638","volume":"19","author":"Sternberg","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0910","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1200\/JCO.1997.15.4.1427","article-title":"Salvage chemotherapy with vinblastine, ifosfamide, and cisplatin in recurrent seminoma","volume":"15","author":"Miller","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0915","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1200\/JCO.1995.13.11.2700","article-title":"Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors","volume":"13","author":"Motzer","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0920","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1038\/sj.bjc.6601676","article-title":"Oral capecitabine vs intravenous 5\u2013fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials","volume":"90","author":"Van Cutsem","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2010.10.013_b0925","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(00)02034-1","article-title":"Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial","volume":"355","author":"Douillard","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2010.10.013_b0930","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/sj.bjc.6600641","article-title":"Phase II study of irinotecan with bolus and high dose infusional 5\u2013FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer","volume":"87","author":"Leonard","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2010.10.013_b0935","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/01.COC.0000020581.59835.7A","article-title":"Bimonthly leucovorin, infusion 5\u2013fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer","volume":"26","author":"Mabro","year":"2003","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0940","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0959-8049(01)00068-5","article-title":"High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7)","volume":"37","author":"Maindrault-Goebel","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2010.10.013_b0945","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1200\/JCO.2004.05.188","article-title":"Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer","volume":"22","author":"Sorbye","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0950","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM200009283431302","article-title":"Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group","volume":"343","author":"Saltz","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2010.10.013_b0955","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1200\/JCO.2003.08.058","article-title":"Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer","volume":"21","author":"Fuchs","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0960","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1038\/sj.bjc.6602172","article-title":"A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer","volume":"91","author":"Schoemaker","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2010.10.013_b0965","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1200\/JCO.2004.01.140","volume":"22","author":"Bouche","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0970","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1200\/JCO.2006.06.8429","article-title":"Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group","volume":"24","author":"Van Cutsem","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0975","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1200\/JCO.2006.08.0135","article-title":"Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research","volume":"25","author":"Roth","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0980","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1038\/sj.bjc.6603133","article-title":"Phase II study of docetaxel and irinotecan combination chemotherapy in metastatic gastric carcinoma","volume":"94","author":"Park","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2010.10.013_b0985","doi-asserted-by":"crossref","first-page":"4543","DOI":"10.1200\/JCO.2002.02.021","article-title":"Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients","volume":"20","author":"Louvet","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b0990","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1002\/1097-0142(20010401)91:7<1316::AID-CNCR1134>3.0.CO;2-0","article-title":"Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma","volume":"91","author":"Shin","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2010.10.013_b0995","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1200\/JCO.1995.13.10.2629","article-title":"Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity","volume":"13","author":"Bui","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b1000","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1200\/JCO.1999.17.9.2676","article-title":"Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study","volume":"17","author":"Rose","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b1005","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1200\/JCO.2004.07.184","article-title":"Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study","volume":"22","author":"Fleming","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b1010","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1093\/jnci\/djp007","article-title":"Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation","volume":"101","author":"Pointreau","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2010.10.013_b1015","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa073149","article-title":"Capecitabine and oxaliplatin for advanced esophagogastric cancer","volume":"358","author":"Cunningham","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2010.10.013_b1020","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1179\/joc.2003.15.2.184","article-title":"Randomized, controlled, multicenter phase III trial of standard-dose fluorouracil\u2013epirubicin\u2013cyclophosphamide (FEC), compared with time-intensive FEC (FEC-G) and mitoxantrone\u2013methotrexate\u2013mitomycin C (MMM-G) in metastatic breast carcinoma","volume":"15","author":"Capotorto","year":"2003","journal-title":"J Chemother"},{"key":"10.1016\/j.ejca.2010.10.013_b1025","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1159\/000086778","article-title":"Weekly dose-dense cisplatin-epirubicin-paclitaxel administration with granulocyte colony-stimulating factor support does not substantially improve prognosis in extensive disease small-cell lung cancer. A SICOG phase II study","volume":"68","author":"Frasci","year":"2005","journal-title":"Oncology"},{"key":"10.1016\/j.ejca.2010.10.013_b1030","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/COC.0b013e31817be954","volume":"32","author":"Heigener","year":"2009","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b1035","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1097\/JTO.0b013e318186fb0d","article-title":"Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303)","volume":"3","author":"Miller","year":"2008","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b1040","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.lungcan.2007.10.001","article-title":"Prophylactic G-CSF and antibiotics enable a significant dose-escalation of triplet-chemotherapy in non-small cell lung cancer","volume":"60","author":"Timmer-Bonte","year":"2008","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejca.2010.10.013_b1045","first-page":"496","article-title":"Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity","volume":"91","author":"Brusamolino","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.ejca.2010.10.013_b1050","first-page":"877","article-title":"Pegfilgrastim as hematopoietic support for dose-dense chemoimmunotherapy with R-CHOP-14 as first-line therapy in elderly patients with diffuse large B cell lymphoma","volume":"15","author":"Mey","year":"2007","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ejca.2010.10.013_b1055","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1093\/annonc\/mdl355","volume":"18","author":"Piedbois","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b1060","first-page":"27","article-title":"A phase III trial comparing R-CHOP 14 and R-CHOP 21 for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin\u2019s lymphoma","author":"Cunningham","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b1065","first-page":"114","article-title":"R-CHOP14 compared to R-CHOP21 in elderly patients with diffuse large B-Cell lymphoma: results of the interim analysis of the LNH03-6B GELA study","author":"Delarue","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.ejca.2010.10.013_b1070","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1592\/phco.27.10.1387","article-title":"Serum pegfilgrastim concentrations during recovery of absolute neutrophil count in patients with cancer receiving pegfilgrastim after chemotherapy","volume":"27","author":"Yang","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ejca.2010.10.013_b1075","doi-asserted-by":"crossref","first-page":"3752","DOI":"10.1200\/JCO.2005.09.071","article-title":"Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732","volume":"23","author":"Niell","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b1080","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/sj.bjc.6604026","article-title":"Intensified dose of cyclophosphamide with G-CSF support versus standard dose combined with platinum in first-line treatment of advanced ovarian cancer a randomised study from the GINECO group","volume":"97","author":"Ray-Coquard","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2010.10.013_b1085","doi-asserted-by":"crossref","unstructured":"217. Lyman G, Kuderer NM, Crawford J, et al. Impact of pegfilgrastim on early all-cause mortality in patients receiving cancer chemotherapy. J Clin Oncol 2008;26. (abstract 6552).","DOI":"10.1200\/jco.2008.26.15_suppl.6552"},{"key":"10.1016\/j.ejca.2010.10.013_b1090","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0002-9343(02)01036-7","article-title":"Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis","volume":"112","author":"Lyman","year":"2002","journal-title":"Am J Med"},{"key":"10.1016\/j.ejca.2010.10.013_b1095","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/00000421-200008000-00017","article-title":"Lenograstim as support for ACE chemotherapy of small-cell lung cancer: a phase III, multicenter, randomized study","volume":"23","author":"Gatzemeier","year":"2000","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b1100","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/sj.bjc.6601708","article-title":"Are prophylactic haematopoietic growth factors of value in the management of patients with aggressive non-Hodgkin\u2019s lymphoma?","volume":"90","author":"Hackshaw","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2010.10.013_b1105","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/(SICI)1097-0142(19980815)83:4<719::AID-CNCR13>3.0.CO;2-V","article-title":"A multicenter randomized Phase II trial of granulocyte-colony stimulating factor-supported, platinum-based chemotherapy with flexible midcycle cisplatin administration in patients with advanced ovarian carcinoma. PSAMOMA Cooperative Group, Spain","volume":"83","author":"Hidalgo","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2010.10.013_b1110","doi-asserted-by":"crossref","unstructured":"Bohlius J, Herbst C, Reiser M, Schwarzer G, Engert A. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma (Review). Cochrane Database Syst Rev 2008 8;(4):CD003189. doi:10.1002\/14651858.CD003189.pub4. 2008.","DOI":"10.1002\/14651858.CD003189.pub4"},{"key":"10.1016\/j.ejca.2010.10.013_b1115","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","article-title":"Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review","volume":"25","author":"Kuderer","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b1120","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/sj.bjc.6604468","article-title":"Patterns of mortality after prolonged follow-up of a randomised controlled trial using granulocyte colony-stimulating factor to maintain chemotherapy dose intensity in non-Hodgkin\u2019s lymphoma","volume":"99","author":"Clamp","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2010.10.013_b1125","unstructured":"Lang K, O\u2019Hea A-M, Eagleton H. Prophylaxis of neutropenic complications during CHOP-R chemotherapy using GCSF: a 3 year case\u2013control study. In: National Cancer Research Institute Cancer Conference, 4\u20137 October, Birmingham, UK; 2009 [abstract C71]."},{"key":"10.1016\/j.ejca.2010.10.013_b1130","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199107183250305","article-title":"Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer","volume":"325","author":"Crawford","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2010.10.013_b1135","first-page":"112","article-title":"The impact of relative dose intensity of rituximab-CHOP on survival in Diffuse Large B-Cell Lymphoma patients","author":"Terada","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.ejca.2010.10.013_b1140","first-page":"112","article-title":"Importance of relative dose intensity for survival in Diffuse Large B-Cell Lymphoma Patients treated with CHOP-Like regimen","author":"Hirakawa","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"10.1016\/j.ejca.2010.10.013_b1145","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1634\/theoncologist.12-12-1416","article-title":"Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim","volume":"12","author":"Balducci","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2010.10.013_b1150","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.ejca.2008.11.021","article-title":"Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropenia management: Results from an integrated analysis","volume":"45","author":"von Minckwitz","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2010.10.013_b1155","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1093\/annonc\/mdl135","volume":"17","author":"Martin","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b1160","unstructured":"Campbell C, Bramwell V, Charette M, Oliver T, and the Systemic Treatment Disease Site Group. The role of colony-stimulating factor (CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer practice guideline report #12-2 (version 2.2003). <http:\/\/www.cancercare.on.ca\/pdf\/pebc12-2s.pdf.2003> [last accessed: Feb 2009]."},{"key":"10.1016\/j.ejca.2010.10.013_b1165","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1200\/JCO.2005.05.645","article-title":"Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials","volume":"23","author":"Clark","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b1170","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/jnci\/93.1.31","article-title":"Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial","volume":"93","author":"Garcia-Carbonero","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2010.10.013_b1175","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1200\/JCO.2003.03.040","article-title":"Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma","volume":"21","author":"Vose","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b1180","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1080\/1042819031000103953","article-title":"Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin\u2019s lymphoma","volume":"44","author":"Grigg","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ejca.2010.10.013_b1185","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1159\/000232580","article-title":"Incidence of febrile neutropenia and myelotoxicity of chemotherapy: a meta-analysis of biosimilar G-CSF studies in breast cancer, lung cancer, and non-Hodgkin\u2019s lymphoma","volume":"32","author":"Engert","year":"2009","journal-title":"Onkologie"},{"key":"10.1016\/j.ejca.2010.10.013_b1190","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1080\/10428190902756081","article-title":"XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy","volume":"50","author":"Engert","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ejca.2010.10.013_b1195","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1186\/1471-2407-8-332","article-title":"XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel\/doxorubicin chemotherapy","volume":"8","author":"del Giglio","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2010.10.013_b1200","doi-asserted-by":"crossref","first-page":"275","DOI":"10.5414\/CPP47275","article-title":"Bioequivalence of two recombinant granulocyte colony-stimulating factor products after subcutaneous injection in healthy volunteers","volume":"47","author":"Lubenau","year":"2009","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.ejca.2010.10.013_b1205","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1097\/JTO.0b013e3181a52964","article-title":"XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy","volume":"4","author":"Gatzemeier","year":"2009","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b1210","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2165\/00063030-200923010-00005","article-title":"Pharmacokinetic and pharmacodynamic profile of new biosimilar filgrastim XM02 equivalent to marketed filgrastim Neupogen: single-blind, randomized, crossover trial","volume":"23","author":"Lubenau","year":"2009","journal-title":"BioDrugs"},{"key":"10.1016\/j.ejca.2010.10.013_b1215","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1093\/annonc\/mdp574","article-title":"Development of a new G-CSF product based on biosimilarity assessment","volume":"21","author":"Gascon","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b1220","unstructured":"EMEA.Questions and Answers on biosimilar medicines (similar biological medicinal products). <http:\/\/www.ema.europa.eu\/pdfs\/human\/pcwp\/7456206en.pdf.2008> [last accessed: 8th March 2010]."},{"key":"10.1016\/j.ejca.2010.10.013_b1225","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1185\/030079907X219599","article-title":"Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials","volume":"23","author":"Pinto","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ejca.2010.10.013_b1230","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1023\/A:1026418831238","article-title":"Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer","volume":"10","author":"Misset","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2010.10.013_b1235","first-page":"280","article-title":"Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain \u2013 results of the LEARN Study","volume":"18","author":"Almenar","year":"2009","journal-title":"Eur J Cancer Care (Engl)"},{"key":"10.1016\/j.ejca.2010.10.013_b1240","first-page":"337","article-title":"Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3\u20134 week chemotherapy regimens in community oncology practices","volume":"13","author":"Morrison","year":"2007","journal-title":"J Manag Care Pharm"},{"issue":"s1","key":"10.1016\/j.ejca.2010.10.013_b1245","first-page":"105","article-title":"Risk of febrile neutropenia and use of G-CSF primary prophylaxis in non-Hodgkin\u2019s Lymphoma patients receiving R-CHOP-21","volume":"93","author":"Haioun","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.ejca.2010.10.013_b1250","first-page":"546","article-title":"Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with high-risk Hodgkin\u2019s lymphoma: results of a phase II study","volume":"91","author":"Engert","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.ejca.2010.10.013_b1255","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3727\/096504008785055549","article-title":"Long-term results of dose-intensive chemotherapy with G-CSF support (TCC-NHL-91) for advanced intermediate-grade non-Hodgkin\u2019s lymphoma: a review of 59 consecutive cases treated at a single institute","volume":"17","author":"Akutsu","year":"2008","journal-title":"Oncol Res"},{"key":"10.1016\/j.ejca.2010.10.013_b1260","unstructured":"EMA. Committee for medicinal products for human use summary of positive opinion for nivestim. <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/001142\/WC500093661.pdf>. [last accessed: 18 October 2010]; 2010."}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804910010294?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804910010294?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:17:28Z","timestamp":1760732248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804910010294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":252,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S0959804910010294"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2010.10.013","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2010.10.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}